Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hyperbaric Oxygen Post Established Stroke (HOPES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02582502
Recruitment Status : Active, not recruiting
First Posted : October 21, 2015
Last Update Posted : March 7, 2019
Sponsor:
Information provided by (Responsible Party):
David Harrison, University of British Columbia

Brief Summary:
The purpose of this study is to examine the role of Hyperbaric Oxygen Therapy (HBOT) in improving neurological function in patients who are 6 to 36 months post ischemic stroke.

Condition or disease Intervention/treatment Phase
Stroke Ischemic Stroke Established Stroke Other: Hyperbaric Oxygen Not Applicable

Detailed Description:

The purpose of this study is to examine the role of Hyperbaric Oxygen Therapy (HBOT) in improving neurological function in patients who are 6 to 36 months post ischemic stroke.

Hyperbaric oxygen therapy (HBOT) involves the administration of inhaled 100% oxygen at increased ambient pressure inside a closed vessel. HBOT produces greatly elevated arterial and tissue oxygen tensions, producing a wide variety of physiological effects at the cellular and sub cellular level. Some of these effects have been postulated to be beneficial in the context of ischemic stroke.

Most of the recovery after stroke occurs in the first 30 to 90 days after the acute event. Recovery is largely based on recovery of brain that is injured, but viable. Physiological imaging studies (PET, EEG) have demonstrated that brain tissue may remain alive but not functional for months or years after ischemic insult.

Subjects will be selected from the stroke population based on an expectation that they would experience a clinically significant improvement. Eligible subjects will have suffered an ischemic stroke involving the cerebral cortex within the last 6 to 36 months. The study will be enrolling 140 subjects and will be randomized to two different treatment arms: experimental group and a waitlist group.

Each subject will receive a series of forty 2 hour treatments, delivered once a day, 5 days a week, within the hyperbaric oxygen chamber.There will be assessments completed before treatment series begins, 3 weeks and 6 weeks into treatment and then again at the end of treatment. After treatment ends, the investigators will conduct these assessments again at 3 months, 6 months, 9 months and 1 year from the date of the participants last treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hyperbaric Oxygen Post Established Stroke - HOPES - Study
Study Start Date : October 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

Arm Intervention/treatment
Experimental: Treatment
This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
Other: Hyperbaric Oxygen
The only intervention given will be 100% oxygen under hyperbaric pressure.

Wait list Treatment
This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
Other: Hyperbaric Oxygen
The only intervention given will be 100% oxygen under hyperbaric pressure.




Primary Outcome Measures :
  1. Change in the Stroke Impact Scale (SIS-16) from baseline over the duration of the study [ Time Frame: Pre treatment (Baseline and after waiting period is completed), During Treatment (3 weeks, 6 weeks) and Post Treatment (9 weeks post baseline, 8 months post and 14 months) ]

Secondary Outcome Measures :
  1. National Institute of Health Stroke Scale (NIHSS) [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  2. Nine hole peg board [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  3. Grip Strength [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  4. Berg Balance Test [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  5. 6 metre walk test [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  6. 6 minutes walk test [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  7. Trail Making Test [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  8. Digital Symbol Substitution Test [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  9. Centre for Epidemiologic Studies Depression Scale (CESD) [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  10. Medical Outcomes Study Short Form (SF-36) [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  11. Montreal Cognitive Assessment (MoCA) [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (9 weeks post baseline, 8 months post and 14 months post) ]
  12. Health Economics Questionnaire [ Time Frame: Pre treatment (Baseline and after waiting period) and Post Treatment (5 months, 8 months, 11 months and 14 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 19 and 85.
  2. Able to speak English and give informed consent or have a substitute decision maker and able to assent.
  3. One or more ischemic stroke(s) involving the cerebral cortex or cerebellum within the last 6 to 36 months
  4. Able to sit in the chamber with the assistance of a waist and chest strap for 120 minutes.

Exclusion Criteria:

  1. Contraindication to HBOT (Appendix C) including:

    1. Untreated collapsed lung (pneumothorax)
    2. Have taken the chemotherapy drug Doxorubicin within 72 hours
    3. Have taken the chemotherapy drug Bleomycin within 4 months
    4. Bowel obstruction
    5. Heart pacemaker of unknown make and model
    6. Pregnancy
    7. Cigarette Smoking
    8. Chronic Obstructive Pulmonary Disease (COPD)
  2. Participation in other stroke related studies.
  3. Previous history stroke > 36 months prior to study baseline

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02582502


Locations
Layout table for location information
Canada, British Columbia
Vancouver General Hospital - Hyperbaric Unit
Vancouver, British Columbia, Canada, V5Z 1M9
Sponsors and Collaborators
University of British Columbia
Investigators
Layout table for investigator information
Principal Investigator: David W Harrison, MD,CCFP(EM),FRCPC Vancouver General Hospital and University of British Columbia

Layout table for additonal information
Responsible Party: David Harrison, Principal Investigator, University of British Columbia
ClinicalTrials.gov Identifier: NCT02582502     History of Changes
Other Study ID Numbers: H15-00766
First Posted: October 21, 2015    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by David Harrison, University of British Columbia:
Hyperbaric Oxygen
HBOT
Hyperbaric Chamber
Pressurized Oxygen
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases